ELI Elite Pharmaceuticals,

Elite Pharmaceuticals, Inc. (AMEX: ELI), a leading drug delivery, specialty pharmaceutical company focused primarily on developing and commercializing proprietary abuse resistant, extended release pain compounds, today announced that the Company will be presenting clinical data on the dose-response reduction of opioid-induced euphoria from naltrexone, at the American Academy of Pain Medicine�s (AAPM) 24th Annual Meeting taking place at the Gaylord Palms Resort in Orlando, FL on February 14-16. Dr. Stuart Apfel, Elite�s Chief Medical Officer, commented, �We are honored to have been selected to present our findings at this year�s AAPM. This study illustrates the fact that varying ratios of the opioid and naltrexone, in a combination formulation, may�impact differently on a subject�s euphoria and related sensations. We are not aware of any previous published studies that demonstrate this observation. The study suggests that the ratio of agonist to antagonist is an important consideration in combination drugs designed to deter tampering or abuse of opioid analgesics.� Lynn Webster, M.D., head of Lifetree Clinical Research in Salt Lake City, and the lead investigator for the abuse-deterrent study, said, "Prescription drug abuse is a national crisis. If we are going to use powerful pain killers like opioids we need them to be less attractive to abuse. Elite is advancing a formulation which may help deter abuse while providing a medication that will be effective in treating intractable pain." About the American Academy of Pain Medicine�s (AAPM�s) 24th Annual Meeting AAPM has evolved as the primary organization for physicians practicing the specialty of pain medicine in the United States. As the practice of pain medicine has grown, a defined body of knowledge and scope of practice have emerged, and today pain medicine is recognized as a discrete specialty by the American Medical Association (AMA). AAPM is the only pain medicine organization with representation in the AMA. The meeting expects to draw more than 800 attendees from across the country practicing in various areas of medicine including: anesthesiology, physical medicine and rehabilitation, neurology, internal medicine, neurosurgery, psychiatry, family practice among others. The educational programming will offer the most current information about the diagnosis, treatment, and management of acute pain, chronic cancer and non-cancer pain, and recurrent pain. About Lifetree Clinical Research Lifetree Clinical Research� is a privately-held company, headquartered in Salt Lake City, Utah. Lifetree�s clinicians are recognized clinical and regulatory thought leaders in protocol design, implementation and oversight. Lifetree is dedicated to supporting the pharmaceutical, device, and biotechnology industries by providing unparalleled service and becoming an indispensable drug development partner. For more detailed information about Lifetree Clinical Research�, please visit www.lifetreeresearch.com. About Elite Pharmaceuticals, Inc. Elite Pharmaceuticals www.elitepharma.com is a specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release products. The Company's strategy includes developing generic versions of controlled release drug products with high barriers to entry and assisting partner companies in the life cycle management of products to improve off-patent drug products. Elite's technology is applicable to develop delayed, sustained or targeted release capsules or tablets. Elite has two products currently being sold commercially and a pipeline of seven drug products under development in the therapeutic areas that include pain management, allergy and infection. The addressable market for Elite's current pipeline of products exceeds $6 billion. Elite formed, together with VGS Pharma, LLC, Novel Laboratories, Inc., as a separate specialty pharmaceutical company for the research, development, manufacturing, licensing and acquisition of specialty generic pharmaceuticals. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of the Company, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The Company undertakes no obligation to update any forward-looking statements.